Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs

Food and Chemical Toxicology

Volumn 47, Issue 9, 2009, Pages 2257-2268

  Gu, Yi ^a,b   Wang, Guang Ji ^a   Sun, Jian Guo ^a   Jia, Yuan Wei ^a   Wang, Wei ^a   Xu, Mei Juan ^a   Lv, Tian ^a   Zheng, Yuan Ting ^a   Sai, Yang ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Hutchison Medipharma Ltd   (China)

Author keywords

Absorption; Distribution; Elimination; Ginsenoside Rh2; Pharmacokinetics

Indexed keywords

GINSENOSIDE RH 2; PROTOPANAXADIOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXCRETION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; FEMALE; GINSENG; HALF LIFE TIME; MALE; MAXIMUM PLASMA CONCENTRATION; MEMBRANE PERMEABILITY; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANIMALS; ANTICARCINOGENIC AGENTS; BIOLOGICAL AVAILABILITY; DOGS; DRUGS, CHINESE HERBAL; FEMALE; GINSENOSIDES; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; LIVER; MALE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

CANIS FAMILIARIS; PANAX GINSENG; RATTUS;

EID: 68049127779     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2009.06.013     Document Type: Article

References (46)

1. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification - the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
2. Attele A.S., Wu J.A., and Yuan C.S. Ginseng pharmacology: multiple constituents and multiple actions. Biochem. Pharmacol. 58 (1999) 1685-1693
3. Bae E.A., Han M.J., Choo M.K., Park S.Y., and Kim D.H. Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities. Biol. Pharm. Bull. 25 (2002) 58-63
4. Bae E.A., Han M.J., Kim E.J., and Kim D.H. Transformation of ginseng saponins to ginsenoside Rh2 by acids and human intestinal bacteria and biological activities of their transformants. Arch. Pharm. Res. 27 (2004) 61-67
5. Bae E.A., Shin J.E., and Kim D.H. Metabolism of ginsenoside Re by human intestinal microflora and its estrogenic effect. Biol. Pharm. Bull. 28 (2005) 1903-1908
6. Balayssac D., Authier N., Cayre A., and Coudore F. Does inhibition of P-glycoprotein lead to drug-drug interactions?. Toxicol. Lett. 156 (2005) 319-329
7. Bhattaram V.A., Graefe U., Kohlert C., Veit M., and Derendorf H. Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine 9 (2002) 1-33
8. Boullata J. Natural health product interactions with medication. Nutr. Clin. Pract. 20 (2005) 33-51
9. Burchell B., and Coughtrie M.W.H. Genetic and environmental factors associated with variation of human xenobiotic gluccuronidation and sulfation. Environ. Health Perspect. 105 (1997) 739-747
10. Cai Z.W., Qian T.X., Ricky N.S., and Wong B. Liquid chromatography-electrospray ionization mass spectrometry for metabolism and pharmacokinetic studies of ginsenoside Rg3. Anal. Chim. Acta 492 (2003) 283-293
11. Cheng C.C., Yang S.M., Huang C.Y., Chen J.C., Chang W.M., and Hsu S.L. Molecular mechanisms of ginsenoside Rh2-mediated G1 growth arrest and apoptosis in human lung adenocarcinoma A549 cells. Cancer Chemother. Pharmacol. 55 (2005) 531-540
12. Chi H., Kim D.H., and Ji G.E. Transformation of ginsenosides Rb2 and Rc from Panax ginseng by food microorganisms. Biol. Pharm. Bull. 28 (2005) 2102-2105
13. Cupp M.J. Herbal remedies: adverse effects and drug interactions. Am. Fam. Physician 59 (1999) 1239-1245
14. Demant E.J., and Jensen P.B. Characterization of the cooperative cross-linking of doxorubicin N-hydroxysuccinimide ester derivatives to water soluble proteins. Biochim. Biophys. Acta 1118 (1991) 83-90
15. Fei X.F., Wang B.X., Tashiro S., Li T.J., Ma J.S., and Ikejima T. Apoptotic effects of ginsenoside Rh2 on human malignant melanoma A375-S2 cells. Acta Pharmacol. Sin. 23 (2002) 315-322
16. Glatt H., Boeing H., Engelke C.E., Ma L., Kuhlow A., Pabel U., Pomplun D., Teubner W., and Meinl W. Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects. Mutat. Res. 482 (2001) 27-40
17. Gu Y., Wang G., Sun J., Jia Y., Xu M., and Wang W. In vitro assessment of plasma protein binding of 20(R)-ginsenoside Rh2 by equilibrium dialysis and LC-MS analysis: a case of species differences. Biol. Pharm. Bull. 29 (2006) 951-956
18. Gu Y., Wang G., Sun J., Xie H., and Jia Y. Development of a sensitive LC-ESI-MS assay for 20(R)-ginsenoside Rh2 and its pharmacokinetic application in dogs: a case for the influence of micronization on traditional Chinese medicine. Int. J. Mass Spectrom. 252 (2006) 11-19
19. Gu Y., Wang G.J., Sun J.G., Jia Y.W., Xie H.T., and Wang W. Quantitative determination of ginsenoside Rh(2) in rat biosamples by liquid chromatography-electrospray ionization mass spectrometry. Anal. Bioanal. Chem. 386 (2006) 2043-2053
20. Ham Y.M., Chun K.H., Choi J.S., Kim D.H., and Lee S.K. SEK1-dependent JNK1 activation prolongs cell survival during G-Rh2-induced apoptosis. Biochem. Biophys. Res. Commun. 304 (2003) 358-364
21. Hao H., Wang G., Cui N., Li J., Xie L., and Ding Z. Pharmacokinetic, absorption and tissue distribution of tanshinone IIA solid dispersion. Planta Med. 72 (2006) 1311-1317
22. Hasegawa H., Lee K.S., Nagaoka T., Tezuka Y., Uchiyama M., and Kadata S. Pharmacokinetics of ginsenoside deglycosylated by intestinal bacteria and its transformation to biologically active fatty acid esters. Biol. Pharm. Bull. 23 (2000) 298-304
23. Jia W.W.G., Bu X.X., Philips D., Yan H., Liu G.Y., Chen X.G., Bush J., and Li G. Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy. Can. J. Physiol. Pharmacol. 82 (2004) 431-437
24. Jin J., Shahi S., Kang H.K., van Veen H.W., and Fan T.P. Metabolites of ginsenosides as novel BCRP inhibitors. Biochem. Biophys. Res. Commun. 345 (2006) 1308-1314
25. Kiefer D., and Pantuso T. Panax ginseng. Am. Fam. Physician 68 (2003) 1539-1542
26. Kim M.K., Lee J.W., Lee K.Y., and Yang D.C. Microbial conversion of major ginsenoside Rb(1) to pharmaceutically active minor ginsenoside Rd. J. Microbiol. 43 (2005) 456-462
27. Kitagawa I., Yoshikawa M., Yoshihara M., Hayashi T., and Taniyama T. Chemical studies of crude drugs (1). Constituents of Ginseng radix rubra. Yakugaku Zasshi 103 (1983) 612-622
28. Lee P.S., Song T.W., Sung J.H., Moon D.C., Song S., and Chung Y.B. Pharmacokinetic characteristics and hepatic distribution of IH-901, a novel intestinal metabolite of ginseng saponin, in rats. Planta Med. 72 (2006) 204-210
29. Nakata H., Kikuchi Y., Tode T., Hirata J., Kita T., Ishii K., Kudoh K., Nagata I., and Shinomiya N. Inhibitory effects of ginsenoside Rh-2 on tumor growth in nude mice bearing human ovarian cancer cells. Jpn. J. Cancer Res. 89 (1998) 733-740
30. Park J.A., Lee K.Y., Oh Y.J., Kim K.W., and Lee S.K. Activation of caspase-3 protease via a Bcl-2-insensitive pathway during the process of ginsenoside Rh2-induced apoptosis. Cancer Lett. 121 (1997) 73-81
31. Popovich D.G., and Kitts D.D. Mechanistic studies on protopanaxadiol, Rh2, and ginseng (Panax quinquefolius) extract induced cytotoxicity in intestinal Caco-2 cells. J. Biochem. Mol. Toxicol. 18 (2004) 143-149
32. Qian T., Cai Z., Wong R.N., and Jiang Z.H. Liquid chromatography/mass spectrometric analysis of rat samples for in vivo metabolism and pharmacokinetic studies of ginsenoside Rh2. Rapid Commun. Mass Spectrom. 19 (2005) 3549-3554
33. Qian T., Cai Z., Wong R.N., Mak N.K., and Jiang Z.H. In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 816 (2005) 223-232
34. Rivory L.P., Pond S.M., and Winzor D.J. The influence of pH on the interaction of lipophilic anthracyclines with bovine serum albumin. Biochem. Pharmacol. 44 (1992) 2347-2355
35. 2 and cryogenic spray-freezing technologies. Drug Dev. Ind. Pharm. 27 (2001) 1003-1015
36. Rubas W., Zezyk N., and Grass G.M. Comparison of the permeability characterization of human colonic epithelium (Caco-2) cell line to colon of rabbit, monkey and dog intestine and human drug absorption. Pharm. Res. 10 (1993) 113-118
37. Singh S.S. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr. Drug Metab. 7 (2006) 165-182
38. Sugita O., Sawada Y., Sugiyama Y., Iga T., and Hanano M. Prediction of drug-drug interaction from in vitro plasma protein binding and metabolism. A study of tolbutamide-sulfonamide interaction in rats. Biochem. Pharmacol. 30 24 (1981) 3347-3354
39. Tawab M.A., Bahr U., Karas M., Wurglics M., and Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab. Dispos. 31 (2003) 1065-1071
40. Toutain P.L., and Bousquet-Melou A. Bioavailability and its assessment. J. Vet. Pharmacol. Ther. 27 (2004) 455-466
41. Toutain P.L., and Bousquet-Melou A. Plasma clearance. J. Vet. Pharmacol. Ther. 27 (2004) 415-425
42. Toutain P.L., and Bousquet-Melou A. Volume of distribution. J. Vet. Pharmacol. Ther. 27 (2004) 441-453
43. Xie H.T., Wang G.J., Chen M., Jiang X.L., Li H., Lv H., Huang C.R., Wang R., and Roberts M. Uptake and metabolism of ginsenoside Rh2 and its aglycon protopanaxadiol by Caco-2 cells. Biol. Pharm. Bull. 28 (2005) 383-386
44. Xie H.T., Wang G.J., Lv H., Sun R.W., Jiang X.L., Li H., Wang W., Huang C.R., and Xu M.J. Development of a HPLC-MS assay for ginsenoside Rh2, a new anti-tumor substance from natural product and its pharmacokinetic study in dogs. Eur. J. Drug Metab. Pharmacokinet. 30 (2005) 63-67
45. Xie H.T., Wang G.J., Sun J.G., Tucker I., Zhao X.C., Xie Y.Y., Li H., Jiang X.L., Wang R., Xu M.J., and Wang W. High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 818 (2005) 167-173
46. Xie X.W., Eberding A., Madera C., Fazli L., Jia W., Goldenberg L., Gleave M., and Guns E.S. Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models. J. Urol. 175 (2006) 1926-1931